41088-85-1

Basic information

• Product Name: carbobenzoxyhomoserine
• Synonyms: carbobenzoxyhomoserine;Cbz-D-Homoserine;N-[(Phenylmethoxy)carbonyl]-D-homoserine;N-[(Benzyloxy)carbonyl]hoMoserine;Cbz-D-HoMoser Cbz-D-HoMoserine Cbz-D-Hse;(R)-2-(((benzyloxy)carbonyl)amino)-4-hydroxybutanoic acid;N-Carbobenzoxy-D-homoserine
• CAS NO: 41088-85-1
• Molecular Formula: C₁₂H₁₅NO₅
• Molecular Weight: 253.2548
• Mol File: 41088-85-1.mol

Chemical Properties

• Boiling Point: 519.9 °C at 760 mmHg
• Flash Point: 268.2 °C
• Appearance: /
• Density: 1.311
• Vapor Pressure: 1.23E-11mmHg at 25°C
• Refractive Index: 1.563
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: carbobenzoxyhomoserine(CAS DataBase Reference)
• NIST Chemistry Reference: carbobenzoxyhomoserine(41088-85-1)
• EPA Substance Registry System: carbobenzoxyhomoserine(41088-85-1)

Safety Data

• Hazardous Substances Data: 41088-85-1(Hazardous Substances Data)

Usage

Uses

Used in Biochemistry Research:
Carbobenzoxyhomoserine is used as a synthetic intermediate for the modification and synthesis of peptides and proteins. Its carbobenzoxy group allows for selective removal during the synthesis process, revealing the free amine group, which is essential for peptide bond formation and protein assembly.
Used in Pharmaceutical Research:
In the pharmaceutical industry, carbobenzoxyhomoserine serves as a key component in the development of peptide and protein-based drugs. Its ability to protect the amine group during synthesis and subsequent selective removal enables the production of specific peptide and protein derivatives with desired biological activities.
Used in Peptide Synthesis:
Carbobenzoxyhomoserine is used as a building block in the synthesis of complex peptides. The carbobenzoxy group provides protection to the amine group, preventing unwanted side reactions and ensuring the correct formation of peptide bonds during the synthesis process.
Used in Protein Engineering:
In protein engineering, carbobenzoxyhomoserine is utilized for the modification of proteins to study their structure, function, and interactions with other molecules. The selective removal of the carbobenzoxy group allows for the introduction of specific amino acid residues or the alteration of protein properties, facilitating the development of novel protein-based therapeutics and diagnostic tools.

InChI:InChI=1/C12H15NO5/c14-7-6-10(11(15)16)13-12(17)18-8-9-4-2-1-3-5-9/h1-5,10,14H,6-8H2,(H,13,17)(H,15,16)

Upstream product

• 498-19-1 L-(-)-homoserine 
• 501-53-1 benzyl chloroformate 
• 6027-21-0 D-homoserine 
• 3588-56-5 N-[(phenylmethoxy)carbonyl]-D-aspartic acid,1,1-dimethylethyl ester 
• 541-41-3 chloroformic acid ethyl ester 

Downstream Products

• 116506-83-3 Caesium; 2-benzyloxycarbonylamino-4-trityloxy-butyrate 
• 116506-88-8 (S)-2-Benzyloxycarbonylamino-4-[(2R,3R,4R,5S)-5-((R)-1,2-dihydroxy-ethyl)-3,4-dihydroxy-tetrahydro-furan-2-yloxy]-butyric acid 
• 116506-89-9 n=1 
• 116506-90-2 n=2 
• 116506-91-3 n=3 
• 116506-92-4 n=4 
• 116536-02-8 n=5 
• 1159502-39-2 (R)-2-benzyloxycarbonylamino-4-hydroxybutyric acid, dicyclohexylamine salt 
• 369611-56-3 (R)-methyl 2-(((benzyloxy)carbonyl)amino)-4-hydroxybutanoate 
• 82179-05-3 (R)-2-benzyloxycarbonylamino-4-bromo-butyric acid methyl ester 
• 1159502-41-6 (R)-2-benzyloxycarbonylamino-4-(diethoxy-phosphoryl)-butyric acid 
• 1159502-40-5 (R)-2-benzyloxycarbonylamino-4-(diethoxy-phosphoryl)-butyric acid methyl ester 
• 1159502-43-8 4-[(R)-2-benzyloxycarbonylamino-4-(diethoxy-phosphoryl)-butyryl]-piperazine-1-carboxylic acid ethyl ester 

Relevant articles and documents

EP300/CREBBP INHIBITOR

The present invention provides a compound having excellent histone acetyltransferase inhibitory activity against EP300 and/or CREBBP, or a pharmacologically acceptable salt thereof. The compound is represented by the following formula (1) or a pharmacologically acceptable salt thereof: wherein ring Q1, ring Q2, R1, R2, R3 and R4 respectively have the same meanings as defined in the specification.

SUBSTITUTED 2-PHENYL-PYRIDINE DERIVATIVES

The present invention relates to compounds of formula I wherein R1, R2, R4, R5, Ra, Rb, n, W and Z are as defined in the application, their preparation and their use as P2Y12 receptor antagonists in the treatment and/or prevention of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis in humans and other mammals.

SUBSTITUTED 2-PHENYL-PYRIDINE DERIVATIVES

The present invention relates to compounds of formula (I) wherein R1, R2, R4, R5, Ra, Rb, n, W and Z are as defined in the application, their preparation and their use as P2Y12 receptor antagonists in the treatment and/or prevention of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis in humans and other mammals.

PHOSPHONIC ACID DERIVATES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS

The invention relates to 2-phenyl-pyrimidine derivatives containing a phosphonic acid motif and their use as P2Y12 receptor antagonists in the treatment and/or prevention of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis in humans and other mammals. (I).

β-Lactones as a new class of cysteine proteinase inhibitors: inhibition of hepatitis A virus 3C proteinase by N-Cbz-serine β-Lactone

Formula presented N-Benzyloxycarbonyl-L-serine β-lactone (1) is shown to irreversibly inactivate the 3C cysteine proteinase of hepatitis A virus (HAV) with kinact = 0.70 min-1, KI = 1.84 x 10-4 M and kinact/KI = 3800 M-1 min-1 at an enzyme concentration of 0.1 μM. Mass spectrometric and HMQC NMR studies using 13C-labeled 1 show that the active site cysteine (Cys-172) thiol of the HAV 3C proteinase attacks the β-position (i.e. C-4) of the oxetanone ring, thereby leading to ring opening and alkylation of the sulfur. In contrast, the enantiomer of this β-lactone, 2, is a reversible competitive inhibitor (Ki = 1.50 x 10-6 M) at similar enzyme concentrations. The β-lactone motif represents a new class of inhibitors of cysteine proteinases.

AMINOBUTANOIC ACID COMPOUNDS HAVING METALLOPROTEASE INHIBITING PROPERTIES

Aminobutanoic acids of the following formula (I): STR1 where R 1-R 5 are a variety of substituents, novel intermediates, a pharmaceutical composition for treating inflammatory diseases, demyelinating diseases, and tumor metastasis, methods for such treatm

SOLID-PHASE SYNTHESIS OF A NATURALLY OCCURING β-(1-5)-LINKED D-GALACTOFURANOSYL HEPTAMER CONTAINING THE ARTIFICAL LINKAGE ARM L-HOMOSERINE

The glycosyl donor 2,3-di-O-benzoyl-5-O-levulinoyl-6-O-pivaloyl-β-D-Galactofuranosyl chloride and properly-protected L-homoserine covalently bound to polystyrene were employed for the stereoregular formation of a D-galactofuranosyl heptamer containing β-(1-5)-interglycosidic bond and a β-linked L-homoserine via a solid phase approach